Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma
Options
Publisher DOI
PubMed ID
20439646
Description
Invasion and migration are key processes of glioblastoma and are tightly linked to tumor recurrence. Integrin inhibition using cilengitide has shown synergy with chemotherapy and radiotherapy in vitro and promising activity in recurrent glioblastoma. This multicenter, phase I/IIa study investigated the efficacy and safety of cilengitide in combination with standard chemoradiotherapy in newly diagnosed glioblastoma.
Date of Publication
2010
Publication Type
Article
Language(s)
en
Contributor(s)
Stupp, Roger | |
Hegi, Monika E | |
Neyns, Bart | |
Goldbrunner, Roland | |
Schlegel, Uwe | |
Clement, Paul M J | |
Grabenbauer, Gerhard G | |
Simon, Matthias | |
Dietrich, Pierre-Yves | |
Pietsch, Torsten | |
Hicking, Christine | |
Tonn, Joerg-Christian | |
Diserens, Annie-Claire | |
Hermisson, Mirjam | |
Krueger, Stefan | |
Picard, Martin | |
Weller, Michael |
Series
Journal of clinical oncology
Publisher
American Society of Clinical Oncology
ISSN
0732-183X
Access(Rights)
metadata.only